A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3122 Capsules in Subjects With Advanced Malignant Tumors

Phase 1 Recruiting 86 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This is the first-in-human clinical study of TQB3122, aiming to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQB3122 in advanced solid tumors, and to preliminarily explore its efficacy in solid tumors.

Timeline

Start: 2026-01-22
Primary completion: 2026-12
Completion: 2026-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TQB3122	Unknown	—	Oral

Indications

No indication recorded.